In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Marinus (MRNS), with a price target of $3. The company’s shares closed yesterday at $1.16, close to its 52-week low of $0.77.
“We find this is the right and not completely unexpected decision considering his enthusiasm in developing ganaxolone, his broad experience in companies and as an investor, as well as the need for strong stewardship at this time.”
According to TipRanks.com, Higgins is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.9% and a 28.6% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.
Marinus has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.54 and a one-year low of $0.77. Currently, Marinus has an average volume of 872.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.